Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Platform to support clinical variant interpretation through probabilistic assessment of functional evidence

Award Number: R44HG012535
ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/23/2023
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

Platform to support clinical variant interpretation through probabilistic assessment of functional evidence - PROJECT SUMMARY Advances in DNA sequencing technology have revolutionized the diagnosis and treatment of disease, including cancer, cardiovascular disease, and neurodegeneration. Accurate clinical interpretation of genetic variants can enable early detection, inform precision treatment plans, and improve patient outcomes. However, the majority of unique variants uncovered by clinical genetic tests have insufficient evidence for confident classification and are therefore categorized as “variants of uncertain significance” (VUS). The uncertainty introduced by VUS impedes diagnosis, delays care, and increases unnecessary medical treatment. Constantiam Biosciences has developed Varify, an innovative platform that addresses the VUS problem at scale by leveraging the recent advent and rapid proliferation of Multiplexed Assays of Variant Effect, or MAVEs, for variant classification. MAVEs generate functional data for thousands of variants in a single experiment and have been shown to enable reclassification of 44% of VUS within each assayed gene. Leveraging these large and complex datasets, however, is challenging and time-consuming for variant scientists at genetic testing companies and diagnostic laboratories, who spend hours manually searching the literature and evaluating MAVE datasets in an ad hoc and error-prone process. There are no commercial platforms that curate the growing body of MAVEs and perform the rigorous analyses required to responsibly apply the data as evidence within classification guidelines established by the American College of Medical Genetics (ACMG) and the Association for Molecular Pathology (AMP). Constantiam’s technology reduces the time spent searching and evaluating MAVE data by 90%, removing a critical barrier by comprehensively curating MAVE data and transforming it into evidence that can be applied towards classification in minutes. During Phase I, Constantiam Biosciences successfully built a prototype of Varify, leveraging breakthroughs in Bayesian inference and probabilistic programming to analyze raw MAVE data for use as evidence. In parallel, we developed a user-facing application, MAVEvidence, for presenting data and generating evidence reports. The progress made in Phase I has laid a strong foundation for the Phase II project, which includes the following aims: 1) Expand Varify to include all MAVEs for cancer genes, and evaluate performance against clinically annotated variants; 2) Evaluate the functional evidence generated by Varify using population data from UK Biobank; and 3) Integrate Varify-derived evidence into MAVEvidence and develop automation capabilities for scalability. This proposed Phase II plan will enable Constantiam to complete development of a first-to-market, commercial-ready functional evidence platform. At the end of Phase II, genetic testing companies and diagnostic labs will be able to purchase Varify + MAVEvidence to reduce the time spent searching and evaluating functional data by 90%, addressing a $435M market opportunity while increasing the actionability of genetic tests for physicians and patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	CONSTANTIAM BIOSCIENCES INC	6306 GRAND SUMMIT CT	KATY	TX	77494	FORT BEND	USA	Human Genome Research	000	3	3/3/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $1,030,156 )
2025	2025	CONSTANTIAM BIOSCIENCES INC	6306 GRAND SUMMIT CT	KATY	TX	77494	FORT BEND	USA	Human Genome Research	000	3	7/28/2025	NON-COMPETING CONTINUATION	$1,030,156
														Subtotal = $1,030,156

Issue Date FY: 2024 ( Subtotal = $1,016,400 )
2024	2024	CONSTANTIAM BIOSCIENCES INC	6306 GRAND SUMMIT CT	KATY	TX	77494	FORT BEND	USA	Human Genome Research	000	2	6/1/2024	COMPETING CONTINUATION	$1,016,400
														Subtotal = $1,016,400

Grand Total All Awards = $2,046,556

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Platform to support clinical variant interpretation through probabilistic assessment of functional evidence

Award Number: R44HG012535

ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/23/2023

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer